CA3128327A1 - A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl - Google Patents

A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl Download PDF

Info

Publication number
CA3128327A1
CA3128327A1 CA3128327A CA3128327A CA3128327A1 CA 3128327 A1 CA3128327 A1 CA 3128327A1 CA 3128327 A CA3128327 A CA 3128327A CA 3128327 A CA3128327 A CA 3128327A CA 3128327 A1 CA3128327 A1 CA 3128327A1
Authority
CA
Canada
Prior art keywords
kar5585
mean
dose
day
kar5417
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128327A
Other languages
English (en)
French (fr)
Inventor
Michelle PALACIOS
Eric J. Gaukel
Stephen A. Wring
Magdalena ALONSO-GAICIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of CA3128327A1 publication Critical patent/CA3128327A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3128327A 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl Pending CA3128327A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798827P 2019-01-30 2019-01-30
US62/798,827 2019-01-30
PCT/IB2020/000074 WO2020157577A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Publications (1)

Publication Number Publication Date
CA3128327A1 true CA3128327A1 (en) 2020-08-06

Family

ID=70285725

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128327A Pending CA3128327A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Country Status (9)

Country Link
US (2) US11607413B2 (cg-RX-API-DMAC7.html)
EP (1) EP3917531A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022518944A (cg-RX-API-DMAC7.html)
KR (1) KR20210133953A (cg-RX-API-DMAC7.html)
CN (1) CN113557022A (cg-RX-API-DMAC7.html)
AU (1) AU2020213746A1 (cg-RX-API-DMAC7.html)
CA (1) CA3128327A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009055A (cg-RX-API-DMAC7.html)
WO (1) WO2020157577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
AU2019382168A1 (en) 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
CN113557022A (zh) 2019-01-30 2021-10-26 阿尔塔万特科学公司 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
CN113784717A (zh) * 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
AU2019382168A1 (en) 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20200188398A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating sarcoidosis-associated pulmonary hypertension
WO2020128614A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
CN113557022A (zh) 2019-01-30 2021-10-26 阿尔塔万特科学公司 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
CN113784717A (zh) * 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药

Also Published As

Publication number Publication date
WO2020157577A8 (en) 2020-10-15
US20200237759A1 (en) 2020-07-30
JP2022518944A (ja) 2022-03-17
US20240041877A1 (en) 2024-02-08
MX2021009055A (es) 2021-10-22
WO2020157577A1 (en) 2020-08-06
CN113557022A (zh) 2021-10-26
AU2020213746A1 (en) 2021-08-19
KR20210133953A (ko) 2021-11-08
EP3917531A1 (en) 2021-12-08
US11607413B2 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
US20240041877A1 (en) Dosage regime and method for treating pulmonary arterial hypertension
US20260091037A1 (en) Methods for increasing sepiapterin plasma exposure
Giorgi et al. Pharmacokinetics of tramadol and its metabolites M1, M2 and M5 in horses following intravenous, immediate release (fasted/fed) and sustained release single dose administration
CA2769531C (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
US12257252B2 (en) Compositions and methods for increasing tetrahydrobiopterin plasma exposure
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
WO2012054813A1 (en) Novel methods for treating breathing disorders or diseases
Lynch III et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
CA3119909A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20240197756A1 (en) Methods of treatment with neuroactive steroids
US10172854B2 (en) Compositions and methods for treating mitochondrial diseases
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
TW201934123A (zh) 預防或治療癌症之包含pi3激酶抑制劑與細胞毒性抗癌物的醫藥組成物
HK40119071A (en) Methods for increasing sepiapterin plasma exposure
KR100701409B1 (ko) 호박산 수마트립탄을 함유하는 약제학적 조성물
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
KR20070091911A (ko) 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
HK1172242B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
HK1172242A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
JP2010222347A (ja) Pde5阻害剤及びカルニチンを含有する医薬組成物